Neuphoria Therapeutics, Inc. (NEUP)
3.06
-0.30
(-8.93%)
USD |
NASDAQ |
Oct 29, 16:00
3.10
+0.04
(+1.31%)
After-Hours: 05:04
Neuphoria Therapeutics Total Liabilities (Quarterly) : 4.109M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.109M |
| March 31, 2026 | 5.385M |
| December 31, 2025 | 6.898M |
| September 30, 2025 | 14.83M |
| Date | Value |
|---|---|
| March 31, 2025 | 4.716M |
| December 31, 2024 | 4.420M |
| September 30, 2024 | 5.847M |
| June 30, 2024 | 10.16M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Agenus, Inc. | 378.54M |
| Amgen, Inc. | 83.95B |
| Anika Therapeutics, Inc. | 46.19M |
| BioCryst Pharmaceuticals, Inc. | 1.012B |
| Imunon, Inc. | 10.80M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 28.71M |
| Shareholders Equity (Quarterly) | 24.60M |
| Debt to Equity Ratio | 0.0014 |
| Current Ratio | 27.85 |
| Net Debt Paydown Yield | 0.11% |